PMID- 31685009
OWN - NLM
STAT- MEDLINE
DCOM- 20200526
LR  - 20200526
IS  - 2523-3548 (Electronic)
IS  - 2523-3548 (Linking)
VI  - 39
IP  - 1
DP  - 2019 Nov 4
TI  - Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic 
      neuroblastoma patients without MYCN amplification.
PG  - 68
LID - 10.1186/s40880-019-0409-1 [doi]
LID - 68
AB  - BACKGROUND: Interphase fluorescence in situ hybridization (FISH) of bone marrow 
      cells has been confirmed to be a direct and valid method to assess the v-myc 
      avian myelocytomatosis viral oncogene neuroblastoma derived homolog (MYCN) 
      amplification in patients with bone marrow metastatic neuroblastoma. MYCN 
      amplification alone, however, is insufficient for pretreatment risk 
      stratification. Chromosome band 11q23 deletion has recently been included in the 
      risk stratification of neuroblastoma. In the present study, we aimed to evaluate 
      the biological characteristics and prognostic impact of 11q23 deletion and MYCN 
      amplification in patients with bone marrow metastatic neuroblastoma. METHODS: We 
      analyzed the MYCN and 11q23 statuses of 101 patients with bone marrow metastatic 
      neuroblastoma using interphase FISH of bone marrow cells. We specifically 
      compared the biological characteristics and prognostic impact of both 
      aberrations. RESULTS: MYCN amplification and 11q23 deletion were seen in 12 
      (11.9%) and 40 (39.6%) patients. The two markers were mutually exclusive. MYCN 
      amplification occurred mainly in patients with high lactate dehydrogenase (LDH) 
      and high neuron-specific enolase (NSE) levels (both P < 0.001), and 
      MYCN-amplified patients had more events (tumor relapse, progression, or death) 
      than MYCN-normal patients (P = 0.004). 11q23 deletion was associated only with 
      age (P = 0.001). Patients with MYCN amplification had poorer outcomes than those 
      with normal MYCN (3-year event-free survival [EFS] rate: 8.3 +/- 8.0% vs. 
      43.8 +/- 8.5%, P < 0.001; 3-year overall survival [OS] rate: 10.4 +/- 9.7% vs. 
      63.5% +/- 5.7%, P < 0.001). 11q23 deletion reflected a poor prognosis only for 
      patients with normal MYCN (3-year EFS rate: 34.3 +/- 9.5% vs. 53.4 +/- 10.3%, 
      P = 0.037; 3-year OS rate: 42.9 +/- 10.4% vs. 75.9 +/- 6.1%, P = 0.048). Those with 
      both MYCN amplification and 11q23 deletion had the worst outcome (P < 0.001). 
      CONCLUSIONS: Chromosome band 11q23 deletion predicts poor prognosis only in bone 
      marrow metastatic neuroblastoma patients without MYCN amplification. Combined 
      assessment of the two markers was much superior to single-marker assessment in 
      recognizing the patients at a high risk of disease progression.
FAU - Yue, Zhi-Xia
AU  - Yue ZX
AD  - Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline 
      of Pediatrics, Ministry of Education, MOE Key Laboratory of Major Diseases in 
      Children Hematology Oncology Center, Beijing Children's Hospital, Capital Medical 
      University, National Center for Children's Health, 56 Nanlishi Road, Beijing, 
      100045, People's Republic of China.
FAU - Xing, Tian-Yu
AU  - Xing TY
AD  - Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline 
      of Pediatrics, Ministry of Education, MOE Key Laboratory of Major Diseases in 
      Children Hematology Oncology Center, Beijing Children's Hospital, Capital Medical 
      University, National Center for Children's Health, 56 Nanlishi Road, Beijing, 
      100045, People's Republic of China.
FAU - Gao, Chao
AU  - Gao C
AD  - Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline 
      of Pediatrics, Ministry of Education, MOE Key Laboratory of Major Diseases in 
      Children Hematology Oncology Center, Beijing Children's Hospital, Capital Medical 
      University, National Center for Children's Health, 56 Nanlishi Road, Beijing, 
      100045, People's Republic of China.
FAU - Liu, Shu-Guang
AU  - Liu SG
AD  - Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline 
      of Pediatrics, Ministry of Education, MOE Key Laboratory of Major Diseases in 
      Children Hematology Oncology Center, Beijing Children's Hospital, Capital Medical 
      University, National Center for Children's Health, 56 Nanlishi Road, Beijing, 
      100045, People's Republic of China.
FAU - Zhao, Wen
AU  - Zhao W
AD  - Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline 
      of Pediatrics, Ministry of Education, MOE Key Laboratory of Major Diseases in 
      Children Hematology Oncology Center, Beijing Children's Hospital, Capital Medical 
      University, National Center for Children's Health, 56 Nanlishi Road, Beijing, 
      100045, People's Republic of China.
FAU - Zhao, Qian
AU  - Zhao Q
AD  - Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline 
      of Pediatrics, Ministry of Education, MOE Key Laboratory of Major Diseases in 
      Children Hematology Oncology Center, Beijing Children's Hospital, Capital Medical 
      University, National Center for Children's Health, 56 Nanlishi Road, Beijing, 
      100045, People's Republic of China.
FAU - Wang, Xi-Si
AU  - Wang XS
AD  - Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline 
      of Pediatrics, Ministry of Education, MOE Key Laboratory of Major Diseases in 
      Children Hematology Oncology Center, Beijing Children's Hospital, Capital Medical 
      University, National Center for Children's Health, 56 Nanlishi Road, Beijing, 
      100045, People's Republic of China.
FAU - Jin, Mei
AU  - Jin M
AD  - Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline 
      of Pediatrics, Ministry of Education, MOE Key Laboratory of Major Diseases in 
      Children Hematology Oncology Center, Beijing Children's Hospital, Capital Medical 
      University, National Center for Children's Health, 56 Nanlishi Road, Beijing, 
      100045, People's Republic of China.
FAU - Ma, Xiao-Li
AU  - Ma XL
AD  - Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline 
      of Pediatrics, Ministry of Education, MOE Key Laboratory of Major Diseases in 
      Children Hematology Oncology Center, Beijing Children's Hospital, Capital Medical 
      University, National Center for Children's Health, 56 Nanlishi Road, Beijing, 
      100045, People's Republic of China. mxl1123@vip.sina.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20191104
PL  - United States
TA  - Cancer Commun (Lond)
JT  - Cancer communications (London, England)
JID - 101723675
RN  - 0 (MYCN protein, human)
RN  - 0 (N-Myc Proto-Oncogene Protein)
SB  - IM
MH  - Abdominal Neoplasms/*genetics/pathology
MH  - Bone Marrow Neoplasms/*genetics/secondary
MH  - Child
MH  - Child, Preschool
MH  - Chromosome Deletion
MH  - *Chromosomes, Human, Pair 11
MH  - Female
MH  - Head and Neck Neoplasms/*genetics/pathology
MH  - Humans
MH  - Infant
MH  - Male
MH  - N-Myc Proto-Oncogene Protein/*genetics
MH  - Neuroblastoma/*genetics/pathology
MH  - Prognosis
MH  - Thoracic Neoplasms/*genetics/pathology
PMC - PMC6829843
OTO - NOTNLM
OT  - 11q23 deletion
OT  - Bone marrow metastasis
OT  - Event-free survival
OT  - Fluorescence in situ hybridization
OT  - Lactate dehydrogenase
OT  - MYCN amplification
OT  - Neuroblastoma
OT  - Neuron-specific enolase
OT  - Overall survival
COIS- The authors declare that they have no competing interests.
EDAT- 2019/11/07 06:00
MHDA- 2020/05/27 06:00
PMCR- 2019/11/04
CRDT- 2019/11/06 06:00
PHST- 2019/03/11 00:00 [received]
PHST- 2019/10/16 00:00 [accepted]
PHST- 2019/11/06 06:00 [entrez]
PHST- 2019/11/07 06:00 [pubmed]
PHST- 2020/05/27 06:00 [medline]
PHST- 2019/11/04 00:00 [pmc-release]
AID - 10.1186/s40880-019-0409-1 [pii]
AID - 409 [pii]
AID - 10.1186/s40880-019-0409-1 [doi]
PST - epublish
SO  - Cancer Commun (Lond). 2019 Nov 4;39(1):68. doi: 10.1186/s40880-019-0409-1.